CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of ...
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very ...
Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has ...
Liberal Democrat leader Sir Ed Davey has said his party offers an alternative to the "extremes" of Reform UK and the Greens, as he hailed gains across England and Scotland. The Lib Dems gained 153 ...
CINCINNATI, December 15, 2025--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol ...
The FDA has greenlighted LIB Therapeutics' third-generation PCSK9 inhibitor, Lerochol, which lowers LDL-C cholesterol and has a convenience edge over its PCSK9 ...
With voter loyalty a distant memory, the Lib Dems’ cost of living policies and criticism of Trump could gain them ground It has been an election buildup dominated by the rise of Reform UK and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results